Comparison · NCT04896008-deaths
Sotatercept vs Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Sotatercept vs Placebo: deaths from any cause. Trial comparisons, record NCT04896008-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04896008-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.151 | 0.0905 | 0.242 | wilson | |
| Risk in group 2 | 0.233 | 0.156 | 0.332 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0814 | -0.198 | 0.0372 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.65 | 0.346 | 1.22 | log | |
| Odds ratio, group 1 over group 2 | 0.588 | 0.271 | 1.27 | log | |
| Number needed to treat, for one fewer death from any cause on Sotatercept than on Placebo | 12.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Sotatercept | Participants on background pulmonary arterial hypertension (PAH) therapy were administered sotatercept by subcutaneous (SC) injection at a starting dose of 0.3 mg/kg, with a target dose of 0.7 mg/kg, every 21 days for up to approximately 26 months. | 13 | 86 | EG000 |
| Group 2 | Placebo | Participants on background PAH therapy were administered placebo by SC injection every 21 days for up to approximately 26 months. | 20 | 86 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Up to approximately 31 months
Source ClinicalTrials.gov
Trial
- Title
- A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
- NCT number
- NCT04896008
- Phases
- PHASE3
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept, Placebo
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Results first posted
- 2025-08-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04896008?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04896008-deaths